Waksal's Kadmon IPO crumbles after raising $75M

medmoney

Unlikely IPO candidate Kadmon ($KDMN) made it out amidst a tough IPO market--and swirling criticisms of its rather infamous current and former management, namely the Waksal brothers. But the company didn’t raise nearly as much as it had hoped--downsizing to a $75 million offering from a planned $100 million early this week.

The biotech priced at the bottom of its proposed share range at $12. In early trading, Kadmon’s share price fell to almost $10, despite elaborate backing from existing shareholders.

To get the deal done, existing investors committed to buying $40 million of the IPO, making them responsible for more than half of the completed financing but lowering the bar greatly for attracting new, public market investors.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Sam Waksal founded Kadmon in October 2010 and headed it as CEO until August 2014. Not surprisingly, this attracted considerable attention at the time given that he had pled guilty to and served jail time for charges related to insider trading at ImClone Systems including securities fraud, bank fraud, wire fraud, obstruction of justice, perjury and related conspiracy charges.

He was cashed out ahead of the IPO with a severance package that could total $25 million. Sam’s brother, Harlan Waksal, founded ImClone, which sold for $6.5 billion in 2008 to Eli Lilly ($LLY). He is now the President and CEO of Kadmon.

The pair has already raised and spent a staggering sum of cash through Kadmon--blowing through more than $675 million in the less than 6 years from its inception to the end of the first quarter. Even with all that fundraising, Kadmon was running on fumes with only $8.6 million in cash at March 31 with a first quarter net loss of $32.8 million.

All that cash has bought the company a pipeline headed by a pair of Phase II candidates: rho-associated coiled-coil kinase 2 (ROCK2) inhibitor KD025, which is in Phase II testing to treat idiopathic pulmonary fibrosis (IPF) and for which Phase II testing is planned in moderate to severe psoriasis and other autoimmune diseases, and oral tyrosine kinase inhibitor (TKI) tesevatinib, which completed a Phase II trial in treatment-naïve non-small cell lung cancer (NSCLC) patients with activating EGFR mutations and is in an ongoing trial in NSCLC with activating EGFR mutations in patients with brain metastases or leptomeningeal disease.

Major investors in Kadmon include Golden Tree Asset Management (18.1% post-IPO stake), Third Point Ventures (13.6%) and 3RP Holdings (7.8%).

- here is the release
- and here is the latest S-1 filing

Related Articles:
Sam Waksal exited Kadmon with $25M severance deal ahead of IPO
Waksal's new biotech spins out its gene therapy biz with an IPO in mind
Waksal's back: Once-jailed biotech chief plots an IPO for his latest play
Waksal's latest biotech play is reportedly trying to go public after two misfires
Waksal brushes off jail time, plots biotech IPOs in a red-hot market
Waksal's post-prison startup runs into more fraud allegations

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.